Clinical experience with a novel glaucoma drainage implant.
Clinical experience with a novel glaucoma drainage implant.
复制标题
新型青光眼引流植入物的临床经验。
DOI：
10.1097/ijg.0b013e3182955d73
复制
发表时间：
2014
影响因子：
2
通讯作者：
Asrani,Sanjay
中科院分区：
文献类型：
--
作者：
Kim,James;Allingham,RRand;Hall,Jason;Klitzman,Bruce;Stinnett,Sandra;Asrani,Sanjay
目的：回顾性评价聚乙烯壳（M4）改良的Ahmed型青光眼瓣膜（AGV）与S2型和FP7型青光眼瓣膜相比减少引流板周围纤维化反应的安全性和有效性。方法：回顾性分析AGV FP7、S2、M4植入患者的病历资料。主要结局指标是累积成功概率，定义为眼压（IOP）在5 - 18 mm Hg之间，IOP降低20%而不丧失光感知，需要额外的降低眼压手术，或去除AGV。结果：FP7、S2、M4分别为76、38、40眼，平均随访时间分别为578±157、662±186、504±158天。FP7组平均IOP从31.0±10.6降至13.9±5.5 mm Hg， S2组平均IOP从33.5±12.1降至15.8±8.1 mm Hg， M4组平均IOP从27.0±12.0降至15.0±4.0 mm Hg （P= 0.31）。FP7、S2和M4组1年累计成功率分别为70%、66%和80%，18个月累计成功率分别为61%、53%和52% （P= 0.99）。并发症组间相似。结论：AGV M4、FP7和S2在1年时无显著差异。需要进一步的随访来确定其长期安全性和有效性。
Purpose:To retrospectively evaluate the safety and efficacy of an Ahmed glaucoma valve (AGV) modified with a polyethylene shell (M4) to reduce the fibrotic reaction around the drainage plate compared with the S2 and FP7 models in patients with glaucoma.Methods:The medical records of patients who underwent implantation of the AGV FP7, S2, and M4 were reviewed. The primary outcome measure was cumulative probability of success, defined as an intraocular pressure (IOP) between 5 and 18 mm Hg and> 20% reduction of IOP without loss of light perception, need for additional IOP-lowering surgical procedures, or removal of AGV.Results:Seventy-six, 38, and 40 eyes received the FP7, S2, and M4 with a mean follow-up time of 578±157, 662±186, and 504±158 days, respectively. The mean IOP was reduced from 31.0±10.6 to 13.9±5.5 mm Hg in the FP7 group, 33.5±12.1 to 15.8±8.1 mm Hg in the S2 group, and 27.0±12.0 to 15.0±4.0 mm Hg in the M4 group at 1 year (P= 0.31). At 1 year, the cumulative probability of success was 70%, 66%, and 80% and at 18 months, 61%, 53%, and 52% in the FP7, S2, and M4 groups, respectively (P= 0.99). Complications were similar among groups.Conclusions:No significant difference was observed between the AGV M4, FP7, and S2 at 1 year. Additional follow-up is required to determine its long-term safety profile and efficacy.